drugset / Trial / NCT05891171
Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
Non-randomizedSequentialOpen-labelTreatment
Summary
The primary purpose of this study is to assess the safety and tolerability of AB598 in participants with advanced malignancies.
Timeline
- Start
- 2023-10-13
- Primary completion
- 2027-09
- Completion
- 2027-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AB598 | Unknown | — | Intravenous |
| Background | Leucovorin | Small molecule | — | — |
| Background | Oxaliplatin | Small molecule | — | — |
| Background | Zimberelimab | Monoclonal antibody | — | — |
| Background | fluorouracil | Small molecule | — | — |